Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

Gain Therapeutics (GANX) Receivables - Net (2020 - 2025)

Gain Therapeutics has reported Receivables - Net over the past 3 years, most recently at $400000.0 for Q3 2025.

  • Quarterly results put Receivables - Net at $400000.0 for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $400000.0 (changed N/A YoY), and the annual figure for FY2021 was $81862.0, up 857.67%.
  • Receivables - Net for Q3 2025 was $400000.0 at Gain Therapeutics, roughly flat from $400000.0 in the prior quarter.
  • Over the last five years, Receivables - Net for GANX hit a ceiling of $400000.0 in Q2 2025 and a floor of $4486.0 in Q1 2021.